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INTRODUCTION
Maternal mortality in Ethiopia remains among the highest in the world (Hogan et al. 2010). Ethiopia is
among the six high burden countries for maternal death, along with Afghanistan, the Democratic Republic
the Congo (DRC), India, Nigeria and Pakistan, which collectively account for roughly 50 percent of all
maternal deaths worldwide. With a current estimate of 676 maternal deaths per 100,000 live births, it is
unlikely that Ethiopia will achieve its Millennium Development Goal (MDG) 5 target of reducing the
maternal mortality ratio by three quarters by 2015 (EDHS 2011, Hogan et al. 2010). The leading causes of
maternal death in Ethiopia are postpartum hemorrhage (PPH), unsafe abortion, infection, pregnancy related
hypertension, and obstructed labor (Koblinsky et al. 2010). Ensuring availability of modern contraceptives
and essential life-saving maternal/RH medicines is a major challenge in Ethiopia, where unmet need is very
high and funding for supplies is almost completely donor dependent (Morrison and Brundage 2012).
A UN Commission Report in 2012 identified 13 life-saving commodities, defined as medicines, medical
devices, and health supplies that effectively address avoidable causes of death during pregnancy and childbirth
that, if more widely accessed and properly used, could significantly reduce preventable deaths among women
(Table 1) (UN Commission Report 2012).
This assessment evaluates the availability of life-saving maternal medicines (oxytocin, misoprostol, MgSO4
and antibiotics), equipment, medical devices, and materials that are essential for basic emergency obstetric and
neonatal care (BEmONC) and safe and clean delivery services within primary health care in Ethiopia.
Table 1: Life-saving commodities within the continuum of care
Reproductive health
Maternal health
Newborn health

Child health

Female condom:
Prevents HIV and
unintended pregnancy

Oxytocin:
Prevents and treats
PPH

Injectable antibiotics:
Treats newborn sepsis

Amoxicillin:
Treats
Pneumonia

Contraceptive implants:
Prevents unintended
pregnancy

Misoprostol:
Prevents and treats
PPH

Antenatal corticosteroids:
Prevents preterm
respiratory distress
syndrome

Emergency contraceptive:
Prevents unintended
pregnancy

MgSO4:
Prevents and treats
pre-eclampsia and
eclampsia

Chlorhexidine:
Prevents umbilical cord
infection

Oral rehydration
salt:
Prevents
dehydration from
diarrhea
Zinc:
Treats diarrhea

Resuscitation devices:
For newborn asphyxia
Source: UN Commission Report 2012
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Figure 1: Structure of Ethiopia’s health system

Specialized Hospitals (13)
(1:3.5-5 million people)
Zonal Hospitals (88)
(1:1-1.5 million people)
District Primary Hospitals (94)
(1:60,000-100,000 people)
HCs (2,689)
(1:25,000 households)
HPs (14,414)
(1:5,000 people)
HEWs
(1:500 households)

Source: FMoH, HSDP IV 2010-2011, 2014-2015, October 2010

The government is the primary health care provider in Ethiopia. The country’s health system is decentralized
and organized into three tiers connected by a referral system (Figure 1). Health centers (HCs) serve as the
first curative referral center from health posts (HPs) for services not provided at the HP level, such as basic
and comprehensive EmONC. HPs are expected to provide clean and safe delivery services, basic
reproductive health (RH) services (family planning, antenatal care, postnatal care), and immunization services.
HCs are expected to provide emergency care in addition to safe and clean delivery and basic RH services
(Raifman et al. 2012). Since 1997, Ethiopia’s Health Sector Development Plans (HSDP), a 20 year strategy of
four consecutive, five year investment programs, have aimed to increase the number of providers and health
care facilities, as well as further develop preventive and curative health care components, and promote private
and NGO participation in the health sector. One of the most ambitious components of the HSDP was the
creation in 2004 of the rural Health Extension Program (HEP). The Federal Ministry of Health (FMoH)
launched HEP to make essential healthcare universal, through community provision of preventive and limited
curative and rehabilitative services (FMoH 2004, Mekbib 2007). In the last decade, the Government of
Ethiopia has been aggressively increasing service coverage in rural areas by constructing additional service
delivery points (from 6191 HPs in 2004-05 to 14,416 in 2009-10) and deploying Health Extension Workers
(HEWs), from 2,737 in 2004 to 34,382 in 2010, as well as community health volunteers (CHVs) at the
community level (FMoH 2010).
The Health Policy and Health Sector Development Plan makes provisions for RH and emphasizes the
importance of access to essential drugs and distribution of contraceptives and commodities at service delivery
points (SDPs). The Plan acknowledges current challenges in supply, including shortages of skilled midwives, a
weak referral system among HCs, lack of adequate EmONC equipment availability, and under-financing for
health services (HSDP-IV 2010-11, 2014-15).
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BACKGROUND
The most effective medicines used to prevent postpartum hemorrhage (PPH)—the leading cause of maternal
death in Ethiopia and worldwide—are oxytocin and misoprostol (WHO 2009, Central Statistical Agency et al.
2008). Oxytocin is recommended by the World Health Organization (WHO) as the first line drug for active
management of the third stage of labor (AMTSL)1 and management of excessive bleeding after childbirth.
Oxytocin is effective sooner than other uterotonic drugs and is widely produced by more than 100
manufacturers globally (MSH 2011), but oxytocin is temperature sensitive and relatively expensive (US$0.18
for 10 IU) (PATH 2008). Misoprostol can be stored at room temperature and is inexpensive; therefore, in low
resource settings, where oxytocin is not often available, misoprostol is the preferred method for PPH
prevention. Among several indications for misoprostol use, however, abortion induction is the indication that
most concerns many people. In some countries, there is a fear that oxytocin is used to hasten labor and is
thus dangerous, but rates of induction and augmentation are relatively low in Ethiopia (POPPHI 2008).
For preventing and treating pre-eclampsia and eclampsia (PE/E), studies show that magnesium sulfate
(MgSO4) is the most effective first line drug of choice (WHO 2011). MgSO4 is administered by intravenous or
intramuscular injection, requiring as many as nine vials for one treatment and costing US $0.10 per mL, and it
is produced by only one global manufacturer and many local manufacturers. Calcium gluconate, a mineral
supplement, is an important antidote to MgSO4 when serious toxicity is suspected (Smith et al. 2013).
Oxytocin, misoprostol, and MgSO4 are all included in the 18th edition of the WHO Model Lists of Essential
Medicines (EML). In Ethiopia, oxytocin is included on the Essential Drug List for PPH prevention and
treatment, and misoprostol is approved for prevention of PPH where oxytocin is not available. MgSO4 (500
mg/mL in 2 mL ampoule; 500 mg/mL in 10 mL ampoule) is included on the WHO EML for severe PE/E
and has been approved for PE/E within Ethiopia national policy. MgSO4 is also currently on the Ethiopian
Essential Drug List and authorized for delivery by midwives, health officers, and clinical nurses at HCs (but
only the loading dose) (FMoH 2012).
Six signal functions are essential for basic emergency obstetric and neonatal care BEmONC: administration
of parenteral antibiotics, oxytocic drugs, anticonvulsants for PE/E, manual removal of placenta, removal of
retained placenta, and assisted vaginal delivery (UNFPA, WHO, UNICEF 1997). Two additional signal
functions—safe blood transfusions and surgery (i.e. cesarean delivery)—constitute the package of eight
essential functions for comprehensive EmONC (CEmONC). More recently, neonatal resuscitation has also
been included in BEmONC. If a facility performs all of the six or seven basic functions routinely, it qualifies
as a BEmONC facility, and if a facility performs all eight or nine functions routinely, it qualifies a CEmONC
facility. In Ethiopia, BEmONC is expected to be routine at the HC level and to perform these functions a
facility must have the necessary life-saving equipment, materials, and supplies (UNICEF and FMoH 2004).
In Ethiopia, all public health facilities obtain essential and vital pharmaceuticals primarily through the
integrated pharmaceuticals logistics system (IPLS), a single reporting and distribution system based on the
overall mandate and scope of the national Pharmaceuticals Fund and Supply Agency. To be successful in
ensuring that patients always receive pharmaceuticals, IPLS must fulfill the Six Rights (the right products, in
the right quality, of the right quantity, at the right place, at the right time, and for the right cost). Among the
pharmaceuticals managed by IPLS are MCH products, laboratory products, nutrition products, and
environmental health and sanitation products (FMoH 2011).
AMTSL consists of three basic procedures completed by a skilled birth attendant: administration of a uterotonic drug within one
minute following the birth, delivery of the placenta with controlled cord traction, and massage of the uterus after the placenta delivers
(POPPHI 2007).
1
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Population Council is supporting the Amhara Bureau of Health to understand gaps in provision of maternal
health services to ultimately accelerate Ethiopia’s progress towards meeting MDG 5. This study assesses the
availability and use of life saving maternal health medicines and equipment at HPs and HCs in Amhara.

OBJECTIVES
The main purpose of this study was to assess the availability and use of supplies and equipment for clean and
safe delivery and EmONC services in Amhara region’s primary healthcare service delivery points (SDPs).
Specifically, this assessment provides current information on the needs, gaps, and challenges regarding
misoprostol availability and use in HPs as well as MgSO4 and oxytocin availability and use in HCs. The
availability of other related products, medical devices, materials and equipment critical for maternal health
services were also assessed, as well as the availability of human resources required for skilled care.
The specific objectives of the assessment are:
1. To examine the availability of maternal health supplies at HPs and HCs in the selected communities;
2. To identify needs, gaps, and challenges that will inform program managers’ strengthening of the primary
health care system with increased availability of maternal health supplies;
3. To determine Amhara Bureau of Health’s readiness for integrating the provision of misoprostol in its
health extension programs;
4. To propose additional strategies for increasing access to maternal health supplies within HPs and HCs.

METHODOLOGY
Selection of health facilities for assessment

The assessment was conducted in 10 woredas (districts) in Amhara region’s North Gondar and West Gojam
zones. Amhara’s population of over 17 million comprises almost one quarter of Ethiopia’s population
(UNFPA 2008). The large majority of Amhara’s population lives in rural areas (87%) and is Orthodox
Christian. Amhara has shown consistently strong reproductive health and family planning (RH/FP) health
indicators compared to other predominantly rural states (EDHS 2005, EDHS 2011). Amhara’s total fertility
rate (TFR) is 4.2, and total FP demand is slightly above the national average of 56 percent (EDHS 2011).
Considerably more currently married women in Amhara (34%) use a contraceptive than the national average
(29%), yet antenatal care (ANC) is still low, at 34 percent from any skilled provider and only seven percent
from HEWs (EDHS 2011).
The sample frame for selecting facilities included all HPs and HCs in the study woredas (or districts), which
provide maternal health services. Woredas were selected in consultation with Amhara district officials. These
woredas have been the focus of ongoing health system strengthening activities, including the Council’s Meserete
Hiwott program. In Meserete Hiwott’s original design, mentors of married girls distributed misoprostol, but later
it focused on strengthening the health system to deliver misoprostol in the same woredas as the original
mentoring program. As a result, district health officials wanted to obtain a descriptive picture of their
district’s readiness for delivering full maternal health services. Woreda health offices provided lists of facilities
from which a sample of HCs and HPs were selected through simple random sampling (SRS), with the goal of
selecting approximately two HPs for every one HC, and at least 30 percent of all facilities. Permission for the
health facility assessments was obtained from the Bureau of Health and Health Departments of North
Gondar and West Gojam zones. At the facilities, detailed information, including the assessment’s purpose
4

and procedure, its benefits, the voluntary nature of participation, and right to stop interviews at any time, was
explained to respondents prior to obtaining informed consent. Interviewees were informed that participation
was anonymous and confidential.
Data collection

A team of professionals from the Amhara Bureau of Health, the zonal Health Departments, and Population
Council coordinated data collection. The team recruited medically trained data collectors, including one health
officer, one midwife, one pharmacy technician, and three nurses, who received a five day training that
included the assessment’s purpose and data collection tool administration. After training, data collectors were
organized into three teams, with two data collectors at each SDP. Depending on facility accessibility and
information availability, each data collection team spent one full day at each SDP for inventories and health
care provider interviews. The assessment team, led by the Council health care provider, worked closely with
the data collectors and provided regular recommendations. The team visited the study facilities to check for
accuracy and completeness of information collected.
Three data collection tools were employed:
1)

Inventory of maternal health supplies and services

All maternal health supplies (medicines, medical devices, materials and equipment) from the selected HPs
and HCs were listed by observing available items and through discussions with providers in charge of
maternal health care services and facility pharmacies. In addition, data on services (ANC, delivery, PNC,
and EmONC) provided within the 12 months preceding the survey were gathered from clinical records,
registration books, or the health management information system (HMIS). Data on supply chain
management issues, including logistics, stock outs and HMIS performance, were assessed.
2)

Healthcare provider interview

All healthcare providers responsible for providing maternal health care services (including ANC, delivery,
and PNC and EmONC) were interviewed using structured and unstructured questionnaires. Providers
were expected to comprise midwives, nurses, health officers, medical doctors, pharmacy technicians,
supply chain managers, and facility heads at HCs. In addition, one of the two HEWs assigned to each HP
were interviewed for insight into their maternal health service practices, particularly misoprostol for PPH
and safe and clean delivery services. Health care provider interviews addressed policy and program issues,
including maternal health supply availability, provider training, knowledge, and skills and practices related
to the administration of medicine and EmONC services. Furthermore, the availability of health care
providers who can provide basic packages of EmONC at the HC level was assessed.
3)

Key informant interviews (KIIs)

The assessment included key informant interviews with policymakers, program managers, and supply
chain managers at woreda, zone, and regional Bureau of Health levels. The goal of KIIs was to generate
information to influence regional policy on maternal health supply availability in the primary health care
system and barriers to availability and provision of care. The KII interview guides included policy and
programmatic issues such as registration of supplies in country, their inclusion on the essential drug list,
provider authorization for administration of misoprostol, oxytocin and MgSO4 at each health facility
level, plans for integrating misoprostol in the Health Extension Program, and treatment guidelines on
maternal supplies administration.
Data were cleaned, coded, and stored in a file using EPI INFO and then imported into SPSS version 15 for
descriptive analysis.
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RESULTS
Inventory data were collected in August 2013 from assessments of 23 HCs and 36 HPs, along with interviews
with 26 HC providers and 36 HEWs. Eight KIIs were also conducted with health managers at zonal health
departments (2), woreda health offices (3), and the Amhara Bureau of Health (2), as well as a supply chain
manager from PFSA. Twenty-eight selected facilities (11 HCs and 17 HPs) are in North Gondar and 32 (12
HCs and 19 HPs) are in West Gojam; a complete list of facilities is included in Appendix 1. All HP providers
interviewed were female HEWs between the ages of 21 and 32. In HCs, three health officers, 18 midwifery
nurses, and five nurses (with diplomas) were interviewed, of whom 10 (38%) were male and 16 (62%) were
female, ranging in age from 22 to 37. Most of these providers worked in the maternal and child health unit
(92%), or less frequently, in the outpatient department (8%). The delivery case management team is the
maternal and child health unit, which provides ANC, delivery, PNC, newborn care, and FP.
Facility characteristics and infrastructure

All HPs and most (74%) HCs in the assessment are rural. Most HCs have robust infrastructure, including
electricity (78%), working toilets (91%), a landline telephone (52%), mobile telephone service (87%), and
computers (78%). Few HPs, however, have electricity (11.1%) and none have access to a landline telephone,
computers, or car, and most (92%) do not have mobile telephone service access. All HPs and HCs do have
access to an ambulance. Complete data on facility infrastructure are included in Appendix 2.
Human resource availability

Available human resources in the HPs were comprised of HEWs only, as expected. Most HCs employed
health officers (96%), midwives (96%), and nurses (100%), but only about half (52%) of HCs had nurses with
formal degrees. Seven (19%) of the HPs assessed reported HEW shortages, while more than half of the HCs
reported human resource shortages (Appendix 3).
Maternal health service availability

Most primary health care services were provided at all HCs (Table 2), but EmONC was not reported at all of
them. All 36 HPs, immunization, FP, PNC, and referral services were available, and most indicated availability
of ANC (97%), safe delivery services (81%), and rapid diagnostic tests for malaria (94%). As expected,
EmONC, safe abortion, postabortion care services, and HIV testing and counseling services were not
available, as these services are not permitted within HPs (Table 3).
Table 2: Service availability, by health facility
Health post
n=36
36 (100%)
35 (97.2%)
29 (80.6%)
36 (100%)
N/A
N/A
N/A
N/A
36 (100%)
N/A
N/A
N/A
36 (100%)
N/A
36 (100%)

Type of service available
Family planning (FP)
Antenatal care (ANC)
Delivery
Postnatal care (PNC)
Emergency obstetric and neonatal care (EmONC)
Safe abortion
Postabortion care (PAC)
Prevention of mother-to-child transmission (PMTCT)
Immunization
Antiretroviral therapy (ART)
Voluntary counseling and testing (VCT)
Sexually transmitted infections (STI)
Nutrition
Laboratory
Referral
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Health center
n=23
23 (100%)
23 (100%)
23 (100%)
23 (100%)
18 (78.3%)
10 (43.5%)
21 (91.3%)
20 (87%)
23 (100%)
7 (30.4%)
21 (91.3%)
23 (100%)
23 (100%)
23 (100%)
23 (100%)

Table 3: Availability of tests, by facility type
Tests Available

Health post
n=36

Health center
n=23

HIV testing

N/A

22 (95.7%)

VDRL testing for syphilis
Blood test for anemia

N/A
N/A

8 (34.8%)
12 (52.2%)

Urine test for protein

N/A

18 (78.3%)

Urine test for glucose

N/A

15 (65.2%)

Blood test for malaria

34 (94.4)

22 (95.7%)

Source of Table 2 and Table 3: Inventory

Basic Emergency Obstetric and Neonatal Care (EmONC) service availability

The availability of all six functions of BEmONC was not universal in the HCs (Table 4, Figure 2). Oxytocin
for PPH was virtually available at all HCs, and almost all had performed manual placenta removal in the
previous 12 months. Less than one third of HCs had performed removal of retained products of conception
using MVA, however, presumably due to lack of equipment or trained providers.
Table 4: EmONC service availability in health centers
Were the following basic emergency obstetric care services performed at least once
during the last 12 months?

Health center
n=23

Parenteral antibiotics for maternal sepsis given in last 12 months?

14 (60.9%)

Parenteral oxytocic for PPH given in last 12 months in this facility?

23 (100%)

Parenteral anticonvulsant for PE/E given in last 12 months in this facility?

8 (34.8%)

Manual removal of placenta performed in last 12 months at this facility?

22 (95.7%)

Removal of retained products of conception performed using MVA in the last 12 months in this facility?

7 (30.4%)

Assisted delivery performed in the last 12 months in this facility?

11 (47.8%)

Source: Healthcare provider interview

Figure 2: Total score of Basic Emergency Obstetric services (BEmONC) available at health centers

Percentage of HCs that performed BEmOC 0-6 signal functions
at least once in the past 12 months
6

13%

5

13%

4
Number of BEmOC
3
signal functions
2
1

22%
44%

Percentage of HCs

4%
0%

0

4%
0%

20%

40%

60%

Source: Healthcare provider interview
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Safe and clean delivery conditions

Clean childbirth practices utilizing the “six cleans” (clean hands, clean surface, clean blade, clean cord tie
clean towel to wrap baby, and clean cloth for mother) are important for averting maternal and neonatal
infections, and are expected to be part of safe and clean delivery practices in HPs, where skilled birth
attendants are virtually unavailable. The condition of the “six cleans” for safe and clean delivery services by
facility is presented in Table 5. Although most HCs had access to the “six cleans,” relatively few (35%) had
clean cloths or baby towels. In HPs, facilities were even less equipped with the “six cleans.”
Table 5: “Six cleans” availability, by type of health facility
Status of maternity rooms
Clean rooms/surface
Clean bed sheet/rubber sheet
Clean/sterile blade
Clean cloth/baby towel for wrapping baby
Clean/sterile cord tie
Adequate water for washing
hands/equipment
Disinfectant/soap

Health post
n=36
16 (44%)
16 (44%)
26 (72.2%)
5 (13.9%)
28 (72.8%)
16(44%)
16(44%)

Health center
n=23
23 (100%)
17 (73.9%)
23 (100%)
8 (34.8%)
23 (100%)
22 (95.7%)
22(95.7%)

Source: Inventory

Equipment, materials, and medical devices for clean and safe delivery and EmONC services availability

Equipment, material, and medical device availability is essential for clean and safe delivery in HPs and
EmONC at HCs. The surveyed HPs had inadequate access to key equipment required for clean and safe
delivery: Many HPs lacked torches, examination couches, resuscitation devices, syringes, and suturing material
necessary for obstetric procedures. HCs were relatively better equipped, as expected, but many HCs also
lacked access to torches, Ambubags, manual vacuum aspirators, and suturing material. See Appendix 4 for
complete data on availability of equipment and materials for safe and clean delivery and EmONC services.
Maternal Medicine availability

Table 6 illustrates maternal medicine availability for HPs and HCs and the percentage of facilities with stock
outs in the 12 months prior to the assessment. Oxytocin was available at all HCs, and only one facility
reported stock outs within the last 12 months. Misoprostol for PPH prevention was available at nine (39%)
HCs for use in safe abortion services and at two (6%) HPs. Only two (8%) HCs, compared with 26 (72%)
HPs, reported stock outs of misoprostol in the last 12 months. MgSO4 was not present at any facility; and
furthermore, all assessed HCs reported that the drug had never been available. Calcium gluconate, a common
MgSO4 antidote, was available at only one (4%) HCs. Complete data maternal medicine availability are
included in Appendix 5.
Table 6: Availability and stock outs of key maternal medicines
Available Maternal Medicines
Oxytocin
Misoprostol
MgSO4
Calcium gluconate
Normal saline
Ringer lactate

Health Post
n=36
N/A

Health Center
n=23
23 (100%)

2 (5.6%)

9 (39.1%)

N/A
N/A
N/A
N/A

0 (0%)
1 (4.3%)
22 (95.7%)
20 (87%)
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Stock outs of maternal medicines
Is oxytocin regularly available at this facility?
Stock outs of oxytocin during the last 12
months?
Is misoprostol regularly available at this facility?
Stock-outs of misoprostol in the last 12
months?
Is MgSO4 regularly available at this facility?

Health Post
n=36
N/A

Health Center
n=26
25 (96.2%)

N/A

1 (3.8%)

2 (5.6%)
26 (72.2%)
N/A

10 (38.5%)
2 (7.7%)
0

Source: Inventory and healthcare provider interviews

Contraceptive availability

The most commonly used contraceptive in Ethiopia, Depo-provera, was available at 23 (100%) HCs and 34
(94%) HPs. Male condoms and combined pills were also available at most HCs and HPs. Progesterone-only
pills were mostly available at HCs but not at HPs. Emergency contraception was available at roughly half of
the HCs assessed, and only five (14%) HPs. Implants were available to varying degrees, depending on type.
See Appendix 6 for more detail.
Guidelines and protocols

Overall, the availability of guidelines, service protocols, and training manuals was poor at both HCs and HPs.
Service protocols for PPH prevention and treatment with oxytocin were available at 11 HCs and only two
HPs. Most (66%) HC providers reported knowing these guidelines “very well,” but most HEWs (58%)
reported knowing them “not well,” and 33 percent stated that the protocols did not even exist (Figure 3).
A training manual on safe and clean delivery, including information on misoprostol for PPH, was available at
few facilities (14% of HPs and 17% of HCs). When asked about misoprostol guidelines, 34 percent of HEWs
reported “not [knowing them] well,” and nearly 20 percent indicated that guidelines do not exist. A large
majority of HC providers reported “not [knowing misoprostol guidelines] well” nor did they know whether
misoprostol was being scaled up for provision in HPs in their respective districts (Figure 3). Three quarters of
HP providers and one third of HC providers were aware that misoprostol had been piloted for home birth in
their districts. And an even greater number of providers (81% of HEWs and 38% of HC providers) reported
that misoprostol was piloted at the HP level in their districts. Nevertheless, most HEWs interviewed said that
misoprostol was not scaled up with either home birth or HP deliveries, and most HC providers did not know
whether misoprostol was scaled up in their districts. Complete data on provider knowledge of expansion of
misoprostol for PPH in the home is presented in Appendix 7.
A protocol for MgSO4 for PE/E was available at few HPs (8%) and less than half of the HCs (48%). Most
HEWs (53%) reported “not [knowing the PE/E protocol] well,” and over 40 percent (42%) did not know it
existed. Most (70%) HC providers reported knowing the MgSO4 guidelines “very well.”
Guidelines and service protocols on EmONC were available in 12 (52%) HCs and only seven (19%) HPs.
Over 50 percent of HC providers reported knowing the EmONC guidelines “very well,” yet at the HP level a
large percentage of HEWS said that no protocol for EmONC was available. Guidelines on safe and clean
delivery were available in about half of the facilities (47% of HPs and 57% of HCs). Most HEWs reported
knowing these guidelines “fairly well” (42%) and “very well” (33%), but 17 percent said there were no
guidelines at their facilities. Most HC providers reported knowing the guidelines “very well” (85%). Complete
data on guideline availability, by facility type, are included in Appendix 8.
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Figure 3. Knowledge of guidelines for key maternal medicines
How well do HEWs know Ocytocin
guidelines for PPH?

How well do HC providers know
Oxytocin guidelines for PPH?

3% 6%
Very well
33%

15%

Fairly well
58%

Very well
Fairly well

19%

Not well

66%

Not well

Do not exist

How well do HEWs know the
misoprostol guidelines for PPH?

How well do HC providers know
Misoprostol guidelines for PPH?

Very well
19%
34%

28%
19%

15%

Fairly well

12%

Not well

73%

Fairly well
Not well

Do not exist

How well do HEWs know guidelines
for PE/E?
0
5%

Very well

How well do HC providers know the
guidelines for PE/E?

Very well
Fairly well

42%
53%

Not well
Do not exist

Very well

27%

Fairly well
3%

70%

Not well

Source: Healthcare provider interview

Provider knowledge, training, and experience

All providers interviewed in HCs and HPs were aware that PPH is one of the five main causes of maternal
mortality; most HC providers stated the other main causes, including PE/E (89%), sepsis (96%), obstructed
labor (80%), and unsafe abortion (89%). HEWs were less informed. Oxytocin was recommended as the drug
of choice for PPH by most HC providers (81%), while 47 percent of HEWs identified misoprostol as the
drug of choice for PPH (Figure 4). Knowledge about MgSO4 was limited among HC providers and HEWs
(Figure 5). Data on provider knowledge, training, and experience are presented in Appendices 9 through 11.
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Figure 4. Knowledge of the drug of choice for the prevention and treatment of PPH
HEWs identify the drug of choice for PPH

Health center providers identify the drug
of choice for PPH

6%

8%

25%

47%

Oxytocin
Ergometrine
Misoprostol
Do not know

22%

0

11%

81%

Oxytocin
Ergometrine
Misoprostol
Do not know

Source: Healthcare provider interview

Figure 5. Knowledge of the drug of choice for PE/E among health center providers
Health center providers identify the drug of choice for PE/E

11%

Magnesium sulfate

8%

Diazepam

12%

Hydralazine
69%

Do not know

Source: Healthcare provider interview

Maternal health managers interviewed at zonal and district levels had insufficient awareness and knowledge of
key maternal health supplies, particularly on the use of misoprostol for PPH and MgSO4 for PE/E. Many
managers interviewed were not aware of the use of MgSO4 as the first line of treatment choice for PE/E, and
most did not know whether misoprostol and MgSO4 were approved nationally. Furthermore, most did not
know which health care providers were authorized to administer MgSO4 and misoprostol.
One maternal health officer indicated a lack of knowledge particularly about MgSO4:
“With regard to MgSO4, frankly speaking, I never know this drug [MgSO4]; I was a little bit
confused with another drug [magnesium trisilicate], which is commonly used for treating
gastric problems … As a professional and member of the woreda health office, we have never
been discussing about [MgSO4]. Even it has never been mentioned by anyone of us in this
office; we have never considered its role in the management of preeclampsia and eclampsia
as other drugs such as diazepam. The woreda health office is expecting to support the health
centers to ensure that life-saving drugs are available at the health facilities; however, I have
never seen MgSO4 in our routine drug requisition and distribution at the health center or
health post level. I have never heard it. Really, this drug is never been used in our facilities.”
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A former health office head explained his gaps in knowledge about misoprostol:
“According to the information given by the Population Council, I think, HEWs are
authorized to administer misoprostol at the health post level, but, I am not sure whether this
is true at the national level. I know only the Population Council’s misoprostol project, which
was implemented in our woreda in few selected kebeles, but I do not know the policy
directions and guidelines for misoprostol for PPH at the national level. Misoprostol is not
included in our routine drug requisition and distribution and even not in the list of drugs for
the health post. We do not receive this drug from the regional Pharmaceutical Fund and
Supplies Agency [PFSA] and we have never requested this agency [PFSA] and the Bureau of
health together other drugs during our routine drug request.”
Roughly half of HEWs interviewed were aware that oxytocin (50%) and misoprostol (53%) are on Ethiopia’s
EDL; in contrast, only 27 percent of HC providers were aware misoprostol is included. Knowledge of
national MgSO4 approval was poor among HEWS (8%), and only 39 percent of HC providers were aware
misoprostol is approved for PPH in Ethiopia. Furthermore, providers had limited knowledge of the
guidelines for professional authorization of misoprostol administration in particular (Figure 6).
Figure 6: Knowledge of professional authorization
Are HEWs authorized by the MOH to
administer misoprostol: HEWs

Are HEWs authorized by the MOH to
administer misoprostol: HC providers

Yes

28%

No
3%

65%

Yes

27%
19%

Do not know

54%

No
Do not know

Source: Healthcare provider interview

One third of HEWs and all HC providers interviewed were trained, during their educations, on oxytocin,
while smaller percentages of the two provider groups had refresher trainings in the last 12 months (28% and
35%, respectively). Significantly fewer providers received training in their professional education for
misoprostol (11% of HEWs and 39% of HC providers); however, refresher training for HEWs on
misoprostol was relatively high (47%). For PE/E prevention and management, 22 percent of HEWs and 88
percent of HC providers received professional education and 17 percent and 27 percent received refresher
training in the last year.
Nearly all providers received training on labor and delivery during their professional education (89% of
HEWs and 100% of HC providers), yet significantly fewer had refresher trainings in the last 12 months (58%
and 39%). All HC providers, and only five (14%) HEWs also received training on complicated labor and birth
during their professional training. Furthermore, only three (8%) HEWS and 19 (73%) HC providers reported
training on EmONC during their professional education. Nearly all HC providers (96%) and half of HEWs
(56%) received training on life-saving maternal health supplies during their professional education; refresher
training in this subject was had by only 35 percent of HC providers and 53 percent of HEWs.
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Most HEWs (61%) have administered misoprostol for PPH, compared to eight percent of HC providers.
Nearly all HC providers (96%) have performed AMTSL with oxytocin. Only 27 percent of HC workers have
ever administered anticonvulsants for PE/E. HC providers’ experience performing EmONC varied: 89
percent have performed manual removal of placenta, but fewer than 50 percent have ever performed assisted
delivery, and only 12 percent have ever removed retained placenta with MVA. In qualitative interviews HC
providers were asked to discuss their experiences in BEmONC. HC providers reported that most women
with obstetric complications were referred to higher hospitals with better management available. Almost all
providers reported that women with PE/E were not managed at HCs because of fear of managing severe
complications and lack of effective medicine, such as MgSO4. Lack of confidence, skills, and effective
medicine were the main reasons stated for not managing women with obstetric complications in HCs.
Supply chain management system

With the support of the USAID/DELIVER project2, Ethiopia is currently implementing the new Integrated
Pharmaceutical Logistic System (IPLS) under the leadership of the Pharmaceutical Fund and Supplies Agency
(PFSA). The primary goal of the new IPLS is enabling facilities to prepare bimonthly commodity request
(orders) to the PFSA hub warehouse that supports them (Figure 7). In this assessment, data were collected to
assess the status of supply chain management system of the facilities, including inventory management of
maternal health supplies and the level of implementation of the IPLS at HP and HC levels.
Figure 7: Overview of pharmaceuticals and information flow in the Integrated Pharmaceuticals Logistics
Systems (IPLS)

International/Local Source

Flow of Pharmaceuticals
Flow of Information

National Health
Program Units

PFSA Central

PFSA Hub
Regional Health
Bureau/Zonal
Health Dept

Regional Health
Bureau/Zonal
Woreda Health
Health Dept
Office

Hospitals
Source: FMoH 2011. Standard Operating
Procedures (SOP) Manual. The
Pharmaceuticals Logistics System in
Health Facilities of Ethiopia. March 2011.

Health Centers

Clients

2

Health Posts

http://deliver.jsi.com

13

The present assessment indicates that 56 percent of HPs and 78 percent of HCs reported implementation of
the new IPLS (Table 7). Only 28 percent of HPs and 13 percent of HCs, however, had stock cards for
monitoring drug stock outs in their facilities. Written inventories of drugs were completed at only 22 percent
of HPs and 44 percent of HCs in the 12 months prior to the assessment.
Table 7: Facility based supply chain management system conditions
Supply chain management system conditions
Does the drug store have adequate space?
Does the facility have adequate shelf for the drug?
Is IPLS in place in this facility?
Does this facility have stock card to monitor the status of drug stock-outs?
Was written inventory made in this facility in the last 12 months?

Health post
(n=36)

Health center
(n=23)

23 (64%)
22 (61%)
20 (55.6%)
10 (28%)
8 (22%)

15 (65%)
12 (52%)
18 (78%)
3 (13%)
10 (44%)

Source: Inventory

DISCUSSION
Availability of maternal health supplies

Oxytocin is recommended for and readily available at HCs, with few stock outs, while misoprostol’s
availability is low in both HCs and HPs. Misoprostol is intended primarily for use in safe abortion at HCs,
whereas in HPs it is intended for PPH prevention. Misoprostol for PPH is included on the national drug list
and is recommended for administration by HEWs in HPs; furthermore, misoprostol has been successfully
piloted in the study region. As a result, regular misoprostol supply should be prioritized, particularly for HPs.
MgSO4 was not available in either HCs or HPs, despite FMoH’s approval and recommendation for its use in
HCs. Additionally, anti-hypertensive drugs labetalol and Nefidipine, as well as calcium gluconate, an antidote
for MgSO4 toxicity, were not available in HCs. The lack of availability of these key life-saving maternal
medicines is a primary concern within the context of reducing maternal mortality due to PE/E in Ethiopia.
Most supplies and materials needed for clean and safe delivery and EmONC services were available in HCs,
but clean cloths for babies, in particular, were in short supply at both HCs and HPs. In addition, lack of
availability of clean rooms, clean bed sheets, and adequate water at HPs remains a concern. Despite the fact
that all HCs are designated to provide EmONC services, about one quarter of HCs did not have these
services available and, in the 12 months prior to assessment, very few HCs reported performing all six or
seven BEmONC signal functions.
Needs, gaps, and challenges

Given that oxytocin is largely available where intended for use, lessons from oxytocin can be applied to other
key maternal medicines, namely misoprostol and MgSO4, which are relatively difficult to access in the health
system. Factors contributing to oxytocin’s availability include its continuous supply through IPLS, its
incorporation within the system (rather than dependent on donor procurement and delivery), and HCs’ ability
to purchase it even with budget constraints. Although misoprostol and MgSO4 are approved for delivery by
certain providers, they are not well integrated in IPLS; instead they are distributed mostly by international
non-governmental organizations and largely dependent on donor funding. Qualitative interviews with
providers and health managers reveal that lack of awareness and inadequate attention for misoprostol and
MgSO4 use contribute to their lack of accessibility, while lack of clear FMoH guidance is another barrier.
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Overall, inadequate HP infrastructure (specifically lack of electricity and clean delivery rooms) continues to
constrain HP and HEW capacity to provide clean and safe delivery services. In addition, at all levels, there is a
need for more robust and reliable data collection of services provided and available equipment.
Finally, accurate and appropriate delivery of services by trained health providers is equally important as RH
supply availability. Currently, lack of availability of well trained, knowledgeable, and experienced health
providers at lower health system levels restricts the delivery of quality maternal and child health services.
Nearly one fifth of the HPs and more than half of HCs reported health provider shortages. HC shortages
occurred mostly among doctors, as well as health officers and nurses (with degrees). Overall knowledge of
guidelines for maternal medicines was relatively poor and in need of improvement. Specifically, knowledge
among HEWs of the five main maternal killers was weak, and provider knowledge of protocols for
misoprostol and MgSO4 was limited. Training on guidelines and service protocols should be formally
integrated into professional education programs of each cadre of healthcare provider at every level of the
health system. Training programs should better emphasize EmONC services, delivery of oxytocin and
misoprostol, and initial and refresher training on safe and clean delivery. All providers should be informed
about which medicines are approved and recommended by the government and each provider should be
knowledgeable about whether it is his/her responsibility to provide a specific medicine or intervention.
Readiness for integrating misoprostol into HEP

This assessment demonstrated that there is significant interest from HPs and HEWs for further integration of
misoprostol in the Health Extension Program. To facilitate this goal, several key changes need to be made.
First, misoprostol must be integrated in to the national supply system. Misoprostol is currently not supplied
by the government or integrated in to the national IPLS, which successfully supplies drugs like oxytocin.
Instead, misoprostol relies on support from NGOs for its supply in HPs, which can be irregular. The
majority of providers interviewed indicated that misoprostol had been supplied only once in their facilities
and that it expired without refill in January 2013. Providers are unclear as to which organization provides
misoprostol and therefore the process through which additional supply may be requested.
Second, providers indicated that there is insufficient training for HEWs on the delivery of misoprostol at the
community level. There are no service protocols or guidelines for HEWs focused on misoprostol delivery at
HPs. Furthermore, it is crucial that HC providers are also informed about misoprostol and its use in HPs,
even if it is not indicated for HC use. Overall, there is a need for better understanding of the use of oxytocin
and misoprostol together to prevent and treat PPH at different levels of the health system.
Finally, many health care providers also acknowledged that a lack of community awareness (and therefore
demand), along with distances to facilities and lack of transportation are also challenges for access to maternal
health supplies, including misoprostol in particular.
Overall recommendations

Ethiopia’s pharmaceutical procurement and supply system is fragile and in need of further support. PFSA was
established only six years ago, in 2007, and as a result, its IPLS is still evolving. The national system is
intended to oversee quantification, procurement, and commodity distribution for the public sector. PFSA is
financially independent and autonomous, and supplies regional nodes who then supply hospitals and woredas,
who in turn supply HCs and HPs. Re-supply is normally monthly or bi-monthly, with emergency supply
requests accepted ad hoc. Although this system has proved successful thus far, not all key medications
(including misoprostol and MgSO4) are currently incorporated.
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Despite a burgeoning local pharmaceutical manufacturing industry in Ethiopia, there is an over-reliance on
imported medications in addition to an over-reliance on the public sector for supply of key medicines.
Although FMoH has recognized the importance of public and private partnerships, there is currently poor
integration and understanding of the private sector’s role in the supply and management of health supplies,
medications, and equipment. In other countries the private sector has begun to utilize mobile and electronic
health technologies to improve data tracking and collection for staffing, infrastructure, and services. Such
technology is virtually nonexistent in Ethiopia; however, FHoH has developed a new eHealth strategy, which
could be supported by public and private actors to ensure successful implementation (FMoH 2013).
Task shifting from ‘skilled’ providers to lower level HEWs has been a model of success in Ethiopia for a wide
range of services. In-service training programs with job aids and checklists for Integrated Management of
Neonatal and Childhood Illnesses (IMNCI) and Integrated Community Case Management (iCCM) pertaining
to child and newborn health are in use, but job aids and checklists for MNCH medicines and services are
under-developed, specifically for MgSO4 and misoprostol. Until recently, MgSO4 was employed for treatment
of pre-eclampsia only in hospitals. MgSO4 is now recommended for use in HCs, where most births occur, but
decentralization of the intervention has yet to be successfully implemented. To further the process of
decentralization to HCs, job aids and checklists for pre-eclampsia should also be supported. Incorporating
refresher trainings on PPH prevention and treatment, treatment of pre-eclampsia, and safe and clean delivery
to regular practice is essential for fully preparing providers at all levels of the system.
Recommendations:
1. Increase availability of key maternal health medicines, supplies, and equipment:



Increase availability of MgSO4 and calcium gluconate at the HC level:




Incorporate MgSO4 in to the national IPLS/PFSA;

Increase availability of misoprostol at the HP level:


Incorporate misoprostol in to the national IPLS/PFSA;



Scale up misoprostol through mainstreaming into the Health Extension Program; this
assessment indicates misoprostol was initiated both in home births and HPs, but not scaled up;



Make available service delivery guidelines, protocols, and standards on misoprostol for PPH at
the HC and HP levels; currently the Bureau of Health does not have these guidelines and
protocols for misoprostol; lower level health managers have insufficient knowledge about it;



Increase availability of supplies and the “six cleans” for clean and safe delivery at HPs;



Increase availability of supplies and medical devices (such as MVA) for EmONC services.

2. Increase awareness and knowledge of service provision guidelines for maternal health:



Further develop job aids and checklists for maternal and reproductive health on:


The five main maternal killers (for HEWS);



Misoprostol for prevention of PPH (for HEWs, HC providers and health managers);



MgSO4 for treatment of PE/E (HC providers and health managers);



At HPs and HCs, make a list of medicines approved and recommended for use available, specifying
the system level at which the drug should be administered;



Make service delivery guidelines, protocols, and standards on EmONC services available;
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Increase demand for key maternal health interventions, supplies and medicines by improving
community awareness.

3. Expand existing training programs for HEWs and HC providers:



Improve routine refresher trainings for all HC providers on EmONC at the HC level;



Improve routine refresher trainings for HEWs on safe and clean delivery for HEWs;



Improve routine refresher trainings on key maternal health medicines for HC providers and HEWs.

4. Increase data collection and evaluation of service provision at the HC and HP level:



Facilitate implementation of FMoH’s eHealth strategy to establish workable m/eHealth systems;



Build public and private partnerships to address challenges in supply chain management.

Dissemination

The findings of this assessment will be disseminated to policymakers, program managers and healthcare
providers at all levels to discuss issues related to strengthening the primary healthcare system by improving
the availability of life-saving maternal health supplies. In the dissemination workshop, special attention will be
paid to the need to integrate misoprostol into the existing health extension program packages to ensure
sustainability and regional scale up. The dissemination workshop may also serve as an advocacy strategy for
creating commitment for misoprostol use to prevent PPH at the community level, where over 90 percent of
births occur at home, without skilled birth attendants, as well as MgSO4 use and availability in HCs.

17

APPENDICES
Appendix 1: Complete list of facilities included in the assessment
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.

Amba-Geworgis Health Center
Sak-Debir Health Post
Kosogie Health Post
Maksegnit Health Center
Work-Demo Health Post
Gedebiye Health Center
Abitira Health post
Wokin Health Cernter
Dil-Amba Health Post
Sertia health post
Chandiba Health Post
Chalia health post
Chilga Health Center
Chandiba Health Center
Sergauj Health Post
Minziro Health center
Hamsa-Fej Health post
Burbax Health post
Bahire-Ginb Health post
Jangua Health post
Chuhit Health Center
Koladiba Health Center
Salj Health post
Abrjaha Health center
Abrjaha health post
Darna Gawrna health post
Meskele-Crstos health post
Doromamay Health center
Amarit Health post
Felege-Hiwot health post
Amarit Health center
Adegoma health post
Arbaytu Ensesa health post
Aunt Menz health center
Rim Health Center
Giga health center
Zemene-Hiwot Health post
Birakat Health center
Tikur Bahir health post
Goshiye Health center
Debre-Mawi health center
Debre-mawi health post
Denbash health post
Lata Health center
Abiro Menor Health post
Wonjeta health post
Mercha health post
Mekene health post
Ambo mesk health post

50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
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Wogelsa heealth post
Sifatira health post
Mankusa Health center
Mana health post
Lata health post
Wojenta health center
Densa Bata health center
Dehna Mariam health post
Kudad health post
Wotet Abay Health center

Appendix 2: Facility Infrastructure
Facility infrastructure
Rural
Urban

Health Posts (36)

Health Centers (23)

36 (100%)

17 (73.9%)

0 (0%)

6 (26.1%)

3 (8.3%)

8 (34.8%)

Well water

12 (33.3%)

3 (13%)

Electricity

4 (11.1%)

18 (78.3%)

0 (0%)

12 (52.2%)

Piped Water

Landline telephone
Mobile service
Computer
Toilet (working)
Car in the facility

33 (91.7%)

20 (87%)

0 (0%)

18 (78.3%)

28 (77.8%)

21 (91.3%)

0 (0%)

3 (13%)

Ambulance in the Woreda

36 (100%)

23 (100%)

Clean delivery room

16 (44.4%)

23 (100%)

Appendix 3: Human Resource Availability
Human Resources

Health Post (36)

Health Center (23)

Medical Doctor/General practitioner)

N/A

0 (0%)

OBGYN

N/A

N/A

Health officer

N/A

22 (95.7%)

Midwives

N/A

22 (95.7%)

Nurses

N/A

23 (100%)

Nurses with degree

N/A

12 (52.2%)

0 (0%)

22 (95.7%)

Pharm tech

N/A

23 (100%)

Junior nurse

N/A

6 (26%)

Health assistants

N/A

2 (8.6%)

Lab tech

Health extension workers

36 (100%)

N/A

HMIS personnel

N/A

10 (43.5%)

Healthcare provider shortage: Doctor

N/A

18 (78.3%)

Healthcare provider shortage: OBGYN

N/A

N/A

Healthcare provider shortage: Health officer

N/A

13 (56.5%)

Healthcare provider shortage: Midwives

N/A

13 (56.5%)

Healthcare provider shortage: Diploma nurse

N/A

12 (52.2%)

Healthcare provider shortage: Degree nurse

N/A

12 (30.95%)

Healthcare provider shortage: Lab tech

N/A

10 (43.5%)

Healthcare provider shortage: Pharm tech

N/A

10 (43.5%)

7 (19.4%)

N/A

Shortage of HEWs
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Appendix 4: Availability of equipment, materials and medical devices for safe and clean delivery and EmONC
Type of equipment, material/medical
device
Torch
BP apparatus
Delivery set (complete)
Stetescope
Refrigerator
Examination couch
Delivery couch
Ambubag (resuscitation device)
Valve syringe (resuscitation device)
Apron
Screen
Baby scale
Adult scale
Fetoscope
Tape meter
Disposable glove
Surgical glove
Thermometer (oral)
Thermometer (axillary )
Thermometer (rectal)
Syringe and needle
Speculum
Cannula
Sponge forceps
Artery forceps
Manual vacuum aspiration (MVA)
D &C set
Kidney dish
Cut Gut (suturing material)
Scissors
Cotton roll
Microscope
Disinfectant/Antiseptic solutions
Savlon
Iodine
Alcohol (70%)

Health post (n=36)

Health center (n=23)

4 (11.1%)
30 (83.3%)
33 (91.7%)
32 (88.9%)
9 (25%)
10 (27.8%)
31 (86.1%)
12 (33.3%)
6 (16.7%)
30 (83.3%)
5 (13.9%)
26 (72.2%)
27 (75%)
34 (94.4%)
23 (63.9%)
25 (69.4%)
27 (75%)
4 (11.1%)
26 (72.2%)
10 (2.8%)
32 (88.9%)
9 (27.3%)
7 (19.4%)
12 (33.3%)
24 (66.7)
N/A
N/A
33 (91.7%)
7 (19.4%)
31 (86.1%)
31 (86.1%)
N/A

11 (47.8%)
22 (95.7%)
21 (91.3%)
23 (100%)
23 (100%)
23 (100%)
23 (100%)
10 (43.5%)
20 (87%)
20 (87%)
21 (91.3%)
15 (65.5%)
23 (100%)
22 (95.7%)
14 (60.9%)
17 (73.9%)
19 (82.6%)
10 (4.3%)
16 (69.6%)
10 (4.3%)
22 (95.7%)
10 (43.5%)
6 (26.1%)
12 (52.2%)
17 (73.9%)
11 (47.8%)
N/A
21 (91.3%)
6 (26.1%)
21 (91.3%)
20 (87%)
23 (100%)

6 (16.7%)
14 (39.9%)
6 (16.7%)

13 (56.5%)
16 (69.6%)
13 (56.5%)

20

Appendix 5: Maternal Medicines
Maternal Medicines
Oxytocin

Health Post (36)

Health Center (23)

N/A

23 (100%)

Misoprostol

2 (5.6%)

9 (39.1%)

Ergometrine

N/A

17 (73.9%)

MgSO4

N/A

0 (0%)

Calcium gluconate

N/A

1 (4.3%)

Diazepam

1 (2.8%)

16 (69.6%)

Hydralizine

1 (2.8%)

13 (56.5%)

Nefidipine

N/A

8 (34.8%)

Methyldopa

N/A

18 (78.3%)

Labetalol

N/A

0 (0%)

Ampicillin injection

N/A

19 (82.6%)

Ampicillin capsule

N/A

23 (100%)

Metronidazole injection

N/A

1 (4.3%)

0 (0%)

23 (100%)

Gentamycin
Folic acid

1 (2.8%)

5 (21.7%)

Ferous sulfate

5 (13.9%)

10 (43.5%)

Vitamin A

31 (86%)

17 (74%)

Normal saline

N/A

22 (95.7%)

Ringer lactate

N/A

20 (87%)

Glucose

5 (13.9%)

22 (95.7%)

Adrenaline

1 (2.8%)

20 (87%)

Erythromaycin
Tetracycline

N/A

23 (100%)

6 (16.7%)

11 (47.8%)

Appendix 6: Contraceptive availability
Contraceptives

Health Post (36)

Health Center (23)

Depo-provera

34 (94.4%)

23 (100%)

Combined pills

23 (63.9%)

17 (73.9%)

Projesterone only pills

1 (2.8%)

20 (87%)

Emergency pills

5 (13.9%)

11 (47.8%)

Jadelle

3 (8.3%)

11 (47.8%)

Implanon

18 (50%)

14 (60.9%)

IUCD
Male condom
Female condom

3 (8.3%)

9 (39.1%)

26 (72.2%)

22 (95.7%)

0 (0%)

0 (0%)

*Note: Norplant was not included in the survey.
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Appendix 7: Expansion and scale-up of misoprostol for PPH

Misoprostol piloted at health post level:
HEWs' perspective

Misoprostol piloted at health post level:
HC providers' perspective

11%
8%

Yes

38%

54%

Yes

No

No

Do not know

Do not know

81%
8%

Misoprostol scaled-up at health post
level: HEWs' perspective

Misoprostol scaled-up at health post
level: HC providers' perspective

38%

17%

No

No

Do not know

Do not know

62%

83%

Appendix 8: Availability of guidelines/service protocols for maternal health care services
Guidelines/Service Protocols

Health Post (36)

Health Center (23)

Prevention of PPH with oxytocin

2 (5.5%)

11 (47.8%)

Treatment of PPH with misoprostol

5 (13.8%)

4 (17.4%)

Prevention/treatment of PE/E

3 (8.3%)

11 (47.8%)

Protocol for FP services

21 (58.3%)

18 (78.3%)

Protocol for EmONC services

7 (19.4%)

12 (52.2%)

Protocol for Focused ANC services

23 (63.8%)

17 (73.9%)

Protocol for PNC services

21 (58.3%)

14 (60.9%)

Protocol for clean and safe delivery services

17 (47.2%)

13 (56.5%)

Protocol for infection prevention/universal precaution

11 (30.5%)

12 (52.2%)
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Appendix 9: Provider Knowledge
Provider Knowledge

Health Post (36)

Health Center (26)

Hemorrhage is one of the 5 main killers

36 (100%)

26 (100%)

PE/E is one of the 5 main killers

22 (61.1%)

23 (88.5%)

Sepsis is one of the 5 main killers

16 (44.4%)

25 (96.2%)

Obstructed labor is one of the 5 main killers

19 (52.8%)

21 (80.8%)

Unsafe abortion is one of the 5 main killers

17 (47.2%)

23 (88.5%)

Is oxytocin on the EDL of the country?

18 (50%)

24 (92.3%)

Is misoprostol on EDL of the country?

19 (52.8%)

7 (26.9%)

Is MgSO4 on EDL of the country?

6 (16.7%)

19 (73.1%)

Is MgSO4 in the national policy of PE/E?

4 (11.1%)

16 (61.5%)

Is MgSO4 approved by the country for PE/E?

3 (8.3%)

19 (73.1%)

Is misoprostol approved by the country for PPH?

23 (63.9%)

10 (38.5%)

Are midwives authorized to perform AMTSL with oxytocin?

24 (66.7%)

26 (100%)

Are HEWs authorized to administer misoprostol for PPH?

25 (69.4%)

14 (53.8%)
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Appendix 10: Provider training
Health Post
(36)

Provider Training

Health Center
(26)

Training on prevention/management of PPH with oxytocin during education

12 (33.3%)

26 (100%)

Refresher training on prevention/management of PPH with oxytocin during last 12
months?

10 (27.8%)

9 (34.6%)

Received training on prevention and management of PPH with misoprostol during
education?

4 (11.1%)

10 (38.5%)

Refresher training on misoprostol in last 12 months?

17 (47.2%)

5 (19.2%)

Training on prevention and management of severe PE/E during education?

8 (22.2%)

23 (88.5%)

Refresher training on PE/E?

6 (16.7%)

7 (26.9%)

Training on normal delivery during education

33 (91.7%)

26 (100%)

Refresher training on normal delivery during last 12 months

23 (63.9%)

10 (38.5%)

Training on complicated labor and birth during education?

5 (13.9%)

26 (100%)

Training on complicated birth in the last 12 months?

5 (13.9%)

9 (34.6%)

Training on life-saving maternal health supplies during pregnancy/childbirth or after
delivery during professional education?

20 (55.6%)

25 (96.2%)

Refresher training on life-saving maternal health supplies during pregnancy/childbirth
or after delivery during last 12 months?

19 (52.8%)

9 (34.6%)

Training on EmONC during professional education?

3 (8.3%)

19 (73.1%)

Refresher training on EmONC in last 12 months?

5 (13.9%)

7 (26.9%)

Training on safe and clean delivery during professional education?

32 (88.9%)

26 (100%)

Refresher on safe and clean delivery in last 12 months?

21 (58.3%)

10 (38.5%)

Appendix 11: Provider experience
Provider Experience

Health Post (36)

Health Center (26)

Ever performed AMTSL with oxytocin

N/A

25 (96.2%)

Ever administer misoprostol for PPH

22 (61.1%)

2 (7.7%)

Ever administered parenteral anticonvulsant drugs for PE/E

N/A

7 (26.9%)

Ever administered parenteral antibiotics for maternal sepsis

N/A

16 (61.5%)

Ever performed manual removal of placenta

N/A

23 (88.5%)

Ever performed removal of retained placenta with MVA

N/A

3 (11.5%)

Ever performed assisted delivery

N/A

11 (42.3%)
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